Neanthine


Literature identifierStudy typeTest dosageEffective dosageEndocrine-mediated endpointsSystems-level perturbations
PMID:11080347IVR3 mg/kg 3 mg/kgDecreased ovarian weightsReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgAbnormal estrous cyclesReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgAffects implantationReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgAlterations in endometrial morphologyReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgAffects ovarian follicles populationReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgAlteration in vaginal morphologyReproductive endocrine-mediated perturbations
IVR3 mg/kg 3 mg/kgChanges in ovarian morphologyReproductive endocrine-mediated perturbations
IVR1 mg/kg 1 mg/kgAffects implantationReproductive endocrine-mediated perturbations
IVR2 mg/kg 2 mg/kgAffects uterine morphologyReproductive endocrine-mediated perturbations
IVR2 mg/kg 2 mg/kgAffects implantationReproductive endocrine-mediated perturbations
IVR2 mg/kg 2 mg/kgChanges in ovarian morphologyReproductive endocrine-mediated perturbations

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.